Literature DB >> 26191284

Changes of Th17/Treg cell and related cytokines in pancreatic cancer patients.

Xiaofang Wang1, Lei Wang1, Qingjiang Mo1, Yuqian Dong1, Guoqiang Wang1, Ankui Ji1.   

Abstract

To explore the mechanism of Th17 cells and Treg cells in the peripheral blood of patients with pancreatic cancer through analyzing the changes of the related genes and cytokines expression. 40 patients were divided into three groups based on clinical staging, and 20 healthy subjects were treated as normal control. Proportion of Th17 cells and Treg cells were detected by flow cytometry. RORα, RORγt, FoxP3, and CTLA-4 expression in peripheral blood mononuclear cells were detected by RT-PCR. IL-10, IL-23, INF-γ, TGF-β, and IL-17 cytokine levels in peripheral blood were determined by enzyme-linked immunosorbent assay (ELISA). The proportion of Th17 cells in peripheral blood of pancreatic cancer patients was lower than that in the normal control, while the proportion of Treg was higher. RORα and RORγt mRNA expression in Th17 cells from pancreatic cancer patients decreased, while FoxP3 and CTLA-4 mRNA expressions in Treg cells increased compared with the normal control. And the correlation analysis revealed that they were significantly correlated with clinical staging. Compared with healthy control, IL-23, IL-17 and INF-γ levels were lower in pancreatic cancer patients, while IL-10 and TGF-β levels were higher. Following the progression of disease, patients in advanced stage exhibited higher level of IL-10 and TGF-β, and lower levels of IL-23 and INF-γ. Pancreatic cancer patients exhibited Th17/Treg balance disorders with higher Treg and lower Th17 cells. They affect cytokine IL-10, IL-23, INF-γ, TGF-β, and IL-17 expression changes mainly through regulating transcription factors such as RORα, RORγt, FoxP3 and CTLA-4, suggesting that Th17/Treg balance disorders plays an important role in the tumorigenesis of pancreatic cancer.

Entities:  

Keywords:  CTLA-4; FoxP3; Pancreatic cancer; RORα and RORγt; Th17/Treg; cytokine

Mesh:

Substances:

Year:  2015        PMID: 26191284      PMCID: PMC4503155     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  18 in total

1.  Requirement for RORgamma in thymocyte survival and lymphoid organ development.

Authors:  Z Sun; D Unutmaz; Y R Zou; M J Sunshine; A Pierani; S Brenner-Morton; R E Mebius; D R Littman
Journal:  Science       Date:  2000-06-30       Impact factor: 47.728

2.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

Review 3.  Regulatory T cells, tumour immunity and immunotherapy.

Authors:  Weiping Zou
Journal:  Nat Rev Immunol       Date:  2006-04       Impact factor: 53.106

Review 4.  Current preventive treatment for recurrence after curative hepatectomy for liver metastases of colorectal carcinoma: a literature review of randomized control trials.

Authors:  Peng Wang; Zhen Chen; Wen-Xia Huang; Lu-Ming Liu
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

Review 5.  Natural killer cells in antiviral defense: function and regulation by innate cytokines.

Authors:  C A Biron; K B Nguyen; G C Pien; L P Cousens; T P Salazar-Mather
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

Review 6.  Sepsis syndromes: understanding the role of innate and acquired immunity.

Authors:  A Oberholzer; C Oberholzer; L L Moldawer
Journal:  Shock       Date:  2001-08       Impact factor: 3.454

Review 7.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

8.  Regulation of surface and intracellular expression of CTLA4 on mouse T cells.

Authors:  M L Alegre; P J Noel; B J Eisfelder; E Chuang; M R Clark; S L Reiner; C B Thompson
Journal:  J Immunol       Date:  1996-12-01       Impact factor: 5.422

9.  Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.

Authors:  Liaomin Peng; Jørgen Kjaergäard; Gregory E Plautz; Mohamed Awad; Judith A Drazba; Suyu Shu; Peter A Cohen
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

10.  Anti-chlamydial Th17 responses are controlled by the inducible costimulator partially through phosphoinositide 3-kinase signaling.

Authors:  Xiaoling Gao; Mathieu Gigoux; Jie Yang; Julien Leconte; Xi Yang; Woong-Kyung Suh
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more
  19 in total

1.  IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer.

Authors:  Bhalchandra Mirlekar; Daniel Michaud; Ryan Searcy; Kevin Greene; Yuliya Pylayeva-Gupta
Journal:  Cancer Immunol Res       Date:  2018-07-06       Impact factor: 11.151

2.  Combinatorial Antitumor Effect of Rapamycin and β-Elemene in Follicular Thyroid Cancer Cells.

Authors:  Jun Zhou; Li-Li He; Xiao-Fei Ding; Qiu-Qi Yuan; Jian-Xin Zhang; Shuang-Chun Liu; Guang Chen
Journal:  Biomed Res Int       Date:  2016-05-04       Impact factor: 3.411

Review 3.  Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis.

Authors:  Erin A Marshall; Kevin W Ng; Sonia H Y Kung; Emma M Conway; Victor D Martinez; Elizabeth C Halvorsen; David A Rowbotham; Emily A Vucic; Adam W Plumb; Daiana D Becker-Santos; Katey S S Enfield; Jennifer Y Kennett; Kevin L Bennewith; William W Lockwood; Stephen Lam; John C English; Ninan Abraham; Wan L Lam
Journal:  Mol Cancer       Date:  2016-10-27       Impact factor: 27.401

4.  The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer.

Authors:  Yuan Mao; Xiaoying Wang; Feng Zheng; Changjun Wang; Qi Tang; Xiaojun Tang; Ning Xu; Huiling Zhang; Dawei Zhang; Lin Xiong; Jie Liang; Jin Zhu
Journal:  Oncotarget       Date:  2016-04-26

5.  Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment.

Authors:  Corinne A Levingston; M Rita I Young
Journal:  Cancers (Basel)       Date:  2017-06-02       Impact factor: 6.639

Review 6.  Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy.

Authors:  Yin Qianmei; Su Zehong; Wang Guang; Li Hui; Gaojian Lian
Journal:  Immunol Res       Date:  2021-07-24       Impact factor: 2.829

7.  Expression and prognostic impact of FZDs in pancreatic adenocarcinoma.

Authors:  Yang Li; Zirong Liu; Yamin Zhang
Journal:  BMC Gastroenterol       Date:  2021-02-22       Impact factor: 3.067

Review 8.  T-Cell Immunity in Pancreatic Cancer.

Authors:  Reham Ajina; Louis M Weiner
Journal:  Pancreas       Date:  2020-09       Impact factor: 3.243

9.  Th17 Cells in Protection from Tumor or Promotion of Tumor Progression.

Authors:  M Rita I Young
Journal:  J Clin Cell Immunol       Date:  2016-06-20

10.  Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer.

Authors:  Emma Eriksson; Jessica Wenthe; Sandra Irenaeus; Angelica Loskog; Gustav Ullenhag
Journal:  J Transl Med       Date:  2016-09-29       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.